Preclinical studies of melanoma and breast cancer have shown that the anti-ALK1 monoclonal antibody (PF-03446962) as monotherapy did not show any significant anti-tumor efficacy but it did enhance tumor growth inhibition of a VEGFR TKI or bevacizumab [23]. This evidence concerns the gene KDR and breast carcinoma.